Piper Sandler Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56
Agios Pharmaceuticals Price Target Announced at $51.00/Share by Scotiabank
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating
Raymond James Upgrades Agios Pharmaceuticals(AGIO.US) to Buy Rating, Announces Target Price $51
Agios Pharmaceuticals Analyst Ratings
Agios Pharmaceuticals Initiated With an Outperform at Raymond James
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $56
Leerink Partners Downgrades Agios Pharmaceuticals(AGIO.US) to Hold Rating, Cuts Target Price to $56
Agios Pharmaceuticals Downgraded to Market Perform From Outperform at Leerink
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $57
Piper Sandler Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56
Agios Pharmaceuticals Analyst Ratings
RBC Capital Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $55
Piper Sandler Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56
Agios Pharmaceuticals Analyst Ratings
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
RBC Capital Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $55
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Piper Sandler Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $55
Agios Pharmaceuticals Analyst Ratings